English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colorectal cancer (CRC) is one of the most common causes of gastrointestinal malignancy and cancer-related death in the clinic (1). Moreover, the number of deaths associated with liver metastases in CRC has exceeded 70% (2). In addition, the overall 5-year survival rate of patients with metastatic CRC in Western countries is only 11%, showing a correlation between the presence or absence of metastasis and the survival of CRC patients (3). Therefore, early detection and treatment are key to improving the prognosis and survival of CRC patients. The incidence and mortality rates of CRC have not yet been significantly reduced because its underlying mechanism is not fully understood. In recent years, with advances in our understanding of tumor molecular biology and the development of genetic engineering, molecular targeted therapy has attracted attention as a new and effective treatment for CRC (4,5). In an early study of melanoma cell lines, Lee et al. found that the KiSS1 gene is closely related to the occurrence and metastasis of various malignant cancers, including Original Article

MicroRNA-124 and microRNA-378 inhibit the proliferation and invasion of colorectal cancer by upregulating KiSS1